<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD012432-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD012432-sec-0008"></div> <div class="table" id="CD012432-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Dental examinations at threeâmonth intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Dental examinations at threeâmonth intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people at risk of MRONJ<br><b>Setting:</b> hospital<br><b>Intervention:</b> dental examinations at threeâmonth intervals and preventive treatments (experimental)<br><b>Comparison:</b> standard care (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with standard care (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with dental examinations at 3âmonth intervals and preventive treatments (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>MRONJ (incidence proportion)</b><br>Diagnostic criteria for MRONJ: nonâhealing exposed bone in mandible or maxilla for longer than 8 weeks without any change of the stage of disease </p> <p>Â </p> <p>Followâup: mean 32 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>233 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>23 per 1000</b><br>(5 to 91) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.10</b><br>(0.02 to 0.39) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>253<br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup><br>Â  </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants: highârisk (i.e. individuals with cancer exposed to intravenous zoledronic acid). </p> <p>The outcome MRONJ was also reported as number of cases per patientâyear (incidence rate): rate ratio 0.18 (95% CI 0.04 to 0.74). </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious risk of bias (high and unbalanced rate of crossovers after randomisation; high dropout rates due to high mortality; failure to adhere to the intentionâtoâtreat principle; mean followâup differed between experimental and control groups) and very serious limitation of indirectness (all male and highârisk patients). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people treated with IV bisphosphonates who need dental extractions<br><b>Setting:</b> hospital<br><b>Intervention:</b> dental extraction protocol with PRGF (experimental)<br><b>Comparison:</b> standard dental extraction protocol without PRGF (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with standard dental extraction protocol without PRGF (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with dental extraction protocol with PRGF (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>MRONJ (incidence proportion)</b><br>Diagnostic criteria of MRONJ: pain, swelling, and nonâhealing exposed necrotic bone or fistulae, or both, with connection to the bone<br>Â  </p> <p>Followâup: 24â60 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>59 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>5 per 1000</b><br>(0 to 89) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.08</b><br>(0.00 to 1.51) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>176<br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants: high risk, i.e. individuals with cancer exposed to IV zoledronic acid</p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>IV:</b> intravenous: <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of evidence by three levels due to imprecision and very serious risk of bias (high or unclear risk of selection bias, performance bias, detection bias, and attrition bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0003"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Subperiosteal wound closure versus epiperiosteal wound closure after tooth extraction for prevention of MRONJ in patients on antiresorptive treatment</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people on antiresorptive treatment<br><b>Setting:</b> hospital<br><b>Intervention:</b> subperiosteal wound closure<br><b>Comparison:</b> epiperiosteal wound closure after tooth extraction </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with epiperiosteal wound closure after tooth extraction</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with subperiosteal wound closure after tooth extraction</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>MRONJ after tooth extraction</b> Assessed with: absence of complete mucosal integrity </p> <p>Â </p> <p>Followâup: 6 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>77 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>7 per 1000</b><br>(0 to 120) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.09</b><br>(0.00 to 1.56) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>132<br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>LOW<sup>1</sup></p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 patients changed intervention from epiperiosteal wound closure to subperiosteal wound closure. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, attrition bias and reporting bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0004"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 4.</span>Â <span class="table-title">Hyperbaric oxygen therapy (HBO) as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>HBO as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ<br><b>Setting:</b> hospital<br><b>Intervention:</b> HBO as an adjunct to conventional therapy (experimental)<br><b>Comparison:</b> conventional therapy (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with conventional therapy (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with HBO therapy as an adjunct to conventional therapy (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJ</b><br>Diagnostic criteria for healing of MRONJ: gingival coverage with no exposed bone </p> <p>Â </p> <p>Followâup: up to 24 months (outcome was measured at last followâup)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>333 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>520 per 1000</b><br>(257 to 1000) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.56</b><br>(0.77 to 3.18) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>46Â </p> <p>(1 RCT)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>HBO:</b> hyperbaric oxygen therapy; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, detection bias, and attrition bias; failure to adhere to the intentionâtoâtreat principle). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0005"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 5.</span>Â <span class="table-title">Autofluorescenceâguided bone surgery (experimental) compared to tetracycline fluorescenceâguided bone surgery (control) for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Autofluorescenceâguided bone surgery (experimental) compared to tetracycline fluorescenceâguided bone surgery (control) for treatment of MRONJ</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ<br><b>Setting:</b> hospital<br><b>Intervention:</b> autofluorescenceâguided bone surgery (experimental)<br><b>Comparison:</b> tetracycline fluorescenceâguided bone surgery (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with tetracycline fluorescenceâguided bone surgery (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with autofluorescenceâguided bone surgery (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJ</b><br>Criteria for healing of MRONJ: mucosal integrity </p> <p>Â </p> <p>Followâup: 1 year</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>889 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>933 per 1000</b><br>(764 to 1000) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.05</b><br>(0.86 to 1.30) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34Â <br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, and detection bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0006"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 6.</span>Â <span class="table-title">Bone morphogenetic proteinâ2 together with plateletârich fibrin (experimental) compared to plateletârich fibrin alone (control) for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Bone morphogenetic proteinâ2 together with plateletârich fibrin (experimental) compared to plateletârich fibrin alone (control) for treatment of MRONJ</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> bone morphogenetic proteinâ2 together with plateletârich fibrin (experimental) </p> <p><b>Comparison:</b> plateletârich fibrin only (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with plateletârich fibrin only (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with bone morphogenetic proteinâ2 adjacent to plateletârich fibrin (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJÂ </b> </p> <p>Defined in the study as full coverage with absence of exposed bone, mucosal swelling and erythema, purulent drainage, intraâ and extra oral fistula and/or any pain or discomfort </p> <p>Â </p> <p>Followâup: 16 weeks post surgery</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>880 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>968 per 1000</b><br>(831 to 1000) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.10</b> (0.94 to 1.29) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>55Â <br>(1 RCT)<br>Â  </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> <p>Â </p> <p>Â </p> <p>Â </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious limitations of imprecision and very serious risk of bias (unclear risk of selection bias, detection bias, high risk of performance bias, attrition bias, reporting bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0007"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 7.</span>Â <span class="table-title">Autofluorescenceâguided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>Autofluorescenceâguided surgery (experimental) compared to conventional surgery (control) for treatment of MRONJ </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> autofluorescence guided surgery (experimental) </p> <p><b>Comparison:</b> conventional surgery (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of Participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with conventional surgery (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with autofluorescence guided surgery (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJÂ </b> </p> <p>Criteria for healing: absence of bone exposure</p> <p>Â </p> <p>Followâup: 1 year (at last followâup)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>867 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>933 per 1000</b><br>(734 to 1000) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.08</b> (0.85 to 1.37) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>30<br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> <p>Â </p> <p>Â </p> <p>Â </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High dropâout rate. 6 patients were excluded due to mortality and no show at followâup appointments. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty Â of the evidence by three levels due to very serious imprecision and serious risk of bias (high selection bias, performance bias, attrition bias, unclear risk of detection bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0008"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 8.</span>Â <span class="table-title">Plateletârich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>Plateletârich fibrin after bone surgery (experimental) compared to surgery alone (control) for treatment of MRONJ </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> plateletârich fibrin (experimental) </p> <p><b>Comparison:</b> conventional (control) </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute risks* (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with surgery alone (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with plateletârich fibrin after bone surgery (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJ</b> Defined as absence of infection and mucosal integrity without fistula </p> <p>Â </p> <p>Followâup: 1 year</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>913 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>958 per 1000</b><br>(824 to 1000) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.05</b> (0.90 to 1.22) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>47<br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> <p>Â </p> <p>Â </p> <p>Â </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The outcome healing of MRONJ was also reported as absence of infection, mucosal integrity without fistula, no need for reâintervention: rate ratio 1.60 (95% CI 1.04 to 2.46). Followâup: 1 year </p> <p>SeeÂ <a href="./references#CD012432-fig-0012">Analysis 8.2</a>. </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to very serious limitation of imprecision and serious risk of bias (unclear selection bias, detection bias, high risk of performance bias, reporting bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0009"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 9.</span>Â <span class="table-title">Concentrated growth factor and primary wound closure (experimental) versus primary wound closure only (control) for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>Concentrated growth factor and primary wound closure compared with primary wound closure only for treatment of MRONJ </p> </td> </tr>
<tr class="separated">
<td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ<br><b>Setting:Â </b>surgical treatment<br><b>Intervention:</b> concentrated growth factor and primary wound closure<br><b>Comparison:</b> primary wound closure only </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with primary wound closure only (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with concentrated growth factor and primary wound closure (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJ</b> Defined as soft tissue healing<br>Assessed with: mucosal integrity (without flap dehiscence or infection) </p> <p>Followâup: 6 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>521 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>286 per 1000</b><br>(89 to 922) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.38</b><br>(0.81 to 2.34) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>28<br>(1 RCT) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup><br>Â  </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels because of serious risk of bias (unclear selection bias, high risk of performance bias), very serious limitation of indirectness (only female participants with osteoporosis) and very serious limitation of imprecision (few participants). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0010"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 10.</span>Â <span class="table-title">Teriparatide 20 Î¼g daily (experimental) versus placebo (control) in addition to standard care for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Teriparatide 20 Î¼g daily compared with placebo for treatment of MRONJ</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people Â with MRONJ </p> <p><b>Settings:</b> outpatient and inpatient treatment </p> <p><b>Intervention:</b> teriparatide 20 Î¼g daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of Participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Quality of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with placebo (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with teriparatide 20 Âµg daily (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJ</b> </p> <p>Primary outcomes were the clinical and radiologic resolution of MRONJ lesions, as evaluated by oral examination and CBCT imaging; secondary outcomes included improvement in MRONJ stage, change in MRONJ lesion size, quality of life, bone mineral density, and evidence of osteoblastic response measured biochemically using P1NP and radiologically using 18Fâfluoride PETâCT imaging </p> <p>Â </p> <p>Last followâup: 52 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>278 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>267 per 1000</b> </p> <p>(87 to 819)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.96 Â </b>(0.31 to 2.95) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â 33</p> <p>(1 RCT)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>LOW<sup>1</sup></p> <p>Â </p> <p>Â </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by two levels due to imprecision and serious risk of bias (unclear selection bias, high risk of attrition bias and reporting bias). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012432-tbl-0011"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 11.</span>Â <span class="table-title">Teriparatide 56.5 Î¼gÂ weekly (experimental) versus teriparatide 20 Î¼g daily (control) in addition to standard care for treatment of MRONJ</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Teriparatide 56.5 Î¼gÂ weekly (experimental) compared with teriparatide 20 Î¼g daily (control) in addition to standard care for treatment of MRONJ</b> </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population:</b> people with MRONJ </p> <p><b>Settings:</b> outpatient and inpatient treatment </p> <p><b>Intervention:</b> teriparatide 56.5 Î¼gÂ weekly in addition to standard care </p> <p><b>Comparison:</b> teriparatide 20 Î¼g daily in addition to standard care </p> </td> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Outcomes</b> </p> </th> <th scope="col" align="" valign="top" colspan="2" rowspan="1" class="headercell table-tint"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Relative effect<br>(95% CI)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Number of participants<br>(studies)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Certainty of the evidence<br>(GRADE)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="2" class="headercell"> <p><b>Comments</b> </p> </th> </tr>
<tr class="separated">
<th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with teriparatide 20 Î¼g daily (control)</b> </p> </th> <th scope="col" align="" valign="top" colspan="1" rowspan="1" class="headercell table-tint"> <p><b>Risk with teriparatide 56.5 ÂµgÂ weekly (experimental)</b> </p> </th> </tr>
<tr class="separated">
<td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Healing of MRONJ</b> </p> <p>Measured changes in MRONJ clinical stage at 6 months after the start of the treatment as clinical course, changes in bone metabolism (using bone scintigraphy), percentage of bone formation on the osteolysis of MRONJ, and measurement of bone turnover markers) </p> <p>Â </p> <p>Followâup: 6 months after start of treatment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>500 per 1000</b> </p> <p>Â </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Â <b>300 per 1000</b> (125 to 721) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.60</b> </p> <p>(0.25 to 1.44)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â 12</p> <p>(1 RCT)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br>VERY LOW<sup>1</sup></p> <p>Â </p> <p>Â </p> <p>Â </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Â </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br><b>CI:</b> confidence interval; <b>MRONJ:</b> medicationârelated osteonecrosis of the jaw;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b><br><b>High certainty:</b>Â we are very confident that the true effect lies close to that of the estimate of the effect.<br><b>Moderate certainty:</b>Â we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br><b>Low certainty:Â </b>our confidence in the effect estimate is limited;Â the true effect may be substantially different from the estimate of the effect.<br><b>Very low certainty:</b>Â we have very little confidence in the effect estimate;Â the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p>1. We downgraded the certainty of the evidence by three levels due to imprecision and very serious risk of bias (unclear selection bias and detection bias, high risk of performance bias, attrition bias and reporting bias). </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
